Cohen Capital Management Inc. bought a new stake in Zogenix, Inc. (NASDAQ:ZGNX) in the 3rd quarter, HoldingsChannel reports. The fund bought 35,508 shares of the company’s stock, valued at approximately $1,761,000.

Several other hedge funds have also recently made changes to their positions in ZGNX. BlueMountain Capital Management LLC purchased a new position in shares of Zogenix in the second quarter valued at $104,000. SG Americas Securities LLC purchased a new position in shares of Zogenix in the third quarter valued at $109,000. FNY Investment Advisers LLC boosted its stake in shares of Zogenix by 3,900.0% in the third quarter. FNY Investment Advisers LLC now owns 3,000 shares of the company’s stock valued at $148,000 after purchasing an additional 2,925 shares during the period. Prudential Financial Inc. purchased a new position in shares of Zogenix in the third quarter valued at $219,000. Finally, Public Employees Retirement Association of Colorado purchased a new position in shares of Zogenix in the third quarter valued at $226,000. Institutional investors and hedge funds own 96.69% of the company’s stock.

Several research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Zogenix from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 24th. Empire upped their target price on shares of Zogenix from $57.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, July 31st. Mizuho reiterated a “buy” rating and set a $69.00 price objective on shares of Zogenix in a research note on Thursday, August 9th. Bank of America assumed coverage on shares of Zogenix in a research note on Friday, September 14th. They set a “buy” rating and a $63.00 price objective on the stock. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Zogenix in a research note on Thursday, August 23rd. They set a “buy” rating and a $71.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $68.60.

In other Zogenix news, EVP Gail M. Farfel sold 7,000 shares of the stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $47.58, for a total transaction of $333,060.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gail M. Farfel sold 6,961 shares of the stock in a transaction on Thursday, October 4th. The shares were sold at an average price of $43.23, for a total transaction of $300,924.03. Following the transaction, the executive vice president now owns 14,104 shares in the company, valued at $609,715.92. The disclosure for this sale can be found here. Corporate insiders own 4.60% of the company’s stock.

NASDAQ ZGNX opened at $40.31 on Wednesday. Zogenix, Inc. has a 12 month low of $32.40 and a 12 month high of $62.75. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -10.03 and a beta of 1.86.

Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($1.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.88) by ($0.20). During the same quarter in the previous year, the company posted ($1.68) EPS. On average, equities research analysts predict that Zogenix, Inc. will post -3.76 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “35,508 Shares in Zogenix, Inc. (ZGNX) Acquired by Cohen Capital Management Inc.” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2018/11/21/35508-shares-in-zogenix-inc-zgnx-acquired-by-cohen-capital-management-inc.html.

About Zogenix

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Featured Story: Technical Analysis of Stocks and What It Means

Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.